Arrowhead Pharmaceuticals, Inc. (ARWR) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Pasadena, CA, 미국. 현재 CEO는 Christopher R. Anzalone.
ARWR 을(를) 보유 IPO 날짜 1993-12-16, 609 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $9.34B.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Pasadena, California, that develops RNA interference (RNAi) therapeutics for the treatment of intractable diseases. The company maintains a diverse clinical pipeline targeting liver diseases, metabolic disorders, cardiovascular conditions, respiratory diseases, and rare genetic disorders, with candidates in Phase 1 through Phase 3 clinical development. Key programs include ARO-AAT for alpha-1 antitrypsin deficiency, ARO-APOC3 for hypertriglyceridemia, ARO-HIF2 for renal cell carcinoma, and JNJ-3989 for chronic hepatitis B, developed under collaboration with Janssen Pharmaceuticals. Through strategic partnerships with leading pharmaceutical companies including Janssen and Takeda, Arrowhead leverages its RNAi platform technology to address genetically validated disease targets across multiple therapeutic areas.
